Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial (Q47255118)

12 January 2018

title

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial (English)

1 reference

12 January 2018

main subject

phase II clinical trial

0 references

vandetanib

1 reference

differentiated thyroid carcinoma

ChEBI release 2020-05-28

ChEBI ID

49960

1 reference

9

1 reference

12 January 2018

author name string

Sophie Leboulleux

1

1 reference

12 January 2018

Lars Bastholt

2

1 reference

12 January 2018

Thomas Krause

3

1 reference

12 January 2018

Christelle de la Fouchardiere

4

1 reference

12 January 2018

Jan Tennvall

5

1 reference

12 January 2018

Ahmad Awada

6

1 reference

12 January 2018

José Manuel Gómez

7

1 reference

12 January 2018

Françoise Bonichon

8

1 reference

12 January 2018

Christine Soufflet

10

1 reference

12 January 2018

Muriel Licour

11

1 reference

12 January 2018

Martin J Schlumberger

12

1 reference

12 January 2018

publication date

14 August 2012

1 reference

12 January 2018

Lancet Oncology Commission

published in

1 reference

12 January 2018

volume

13

1 reference

12 January 2018

issue

9

1 reference

12 January 2018

page(s)

897-905

1 reference

12 January 2018

Contemporary post surgical management of differentiated thyroid carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Approach to the patient with advanced differentiated thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Motesanib diphosphate in progressive differentiated thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumors: An Open-Label, Phase I, Rising Multiple-Dose Study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Vandetanib: in medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Phase II trial of sorafenib in advanced thyroid cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

A phase II study of gefitinib in patients with advanced thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(12)70335-2

7 January 2021

10.1016/S1470-2045(12)70335-2

Identifiers

DOI

1 reference

12 January 2018

1 reference

12 January 2018